Chance Pharmaceuticals
PrivateLast Round
IPO
Oct 8, 2025
Est. Valuation
$779.1M
Total Funding Raised
$257.86M
Company Overview
Chance Pharmaceuticals operates in Healthcare & Life Sciences and is based in Hangzhou. Its latest recorded funding round was an Early Funding round in March 2025.
Chance Pharmaceuticals is a clinical-stage biotechnology company that specializes in the discovery, development, and commercialization of innovative dry powder inhalation (DPI) therapies for respiratory, central nervous system, and fibrotic diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Medical Devices, Drug Discovery
Business Model
B2B
Customer Profile
Revenue Share, Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Chance Pharmaceuticals Comparables
Compare Chance Pharmaceuticals with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Zhejiang Xina Pharmaceutical Co., Ltd. | 78% | |
| Suzhou Inhal Pharma Co., Ltd. | 77% | |
| Transpire Bio Inc. | 77% |
For institutional investors. Book with your work email.
Chance Pharmaceuticals Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| IPO | Oct 8, 2025 | ||||
| Early Funding | Mar 17, 2025 | ||||
| Series C Extension | Jan 4, 2022 | ||||
| Series C | Oct 11, 2021 | ||||
| Series F | Jul 2, 2020 | ||||
Series E | Jan 2, 2020 |
For institutional investors. Book with your work email.
Chance Pharmaceuticals Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| BioTrack Capital | Series F |
| Longmen Capital | Series D |
| Oriza Holdings | Series E |
| 招银国际金融有限公司 | IPO |
| SDIC Innovation Investment Management | Series D |
| China Merchants Securities | Series C |
| Lapam Capital | Series C |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- May 20, 2026
Monthly visitors increased 66% MoM.
- Sep 26, 2025
$78M raised with CITIC Securities and Zhaoyin International leading.
For institutional investors. Book with your work email.
Chance Pharmaceuticals Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Chance Pharmaceuticals's valuation, stock price, and market status.
Is Chance Pharmaceuticals a public or private company?
Chance Pharmaceuticals is a private company.
What is the current stock price of Chance Pharmaceuticals?
Chance Pharmaceuticals is a private company, so its shares have no public market price. Caplight tracks Chance Pharmaceuticals's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Chance Pharmaceuticals worth (valuation)?
Chance Pharmaceuticals's valuation is estimated at $779.1M based on funding round data.
Can I buy Chance Pharmaceuticals stock?
Chance Pharmaceuticals shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Chance Pharmaceuticals's last funding round?
Chance Pharmaceuticals's most recent funding round was IPO on October 8, 2025.
Who are the main investors in Chance Pharmaceuticals?
Key investors in Chance Pharmaceuticals include BioTrack Capital, 招银国际金融有限公司, SDIC Innovation Investment Management, Lapam Capital, Shenzhen Dachen Caizhi Venture Capital Management.
Will Chance Pharmaceuticals IPO soon?
No public IPO plans have been announced for Chance Pharmaceuticals.
How can I track Chance Pharmaceuticals secondary market activity?
Caplight tracks bids, offers, and trades in Chance Pharmaceuticals's shares on secondary markets.